{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-23-000035","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2023-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.187828+00:00","generated_at":"2026-06-09T16:55:51.727164+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amneal raises FY 2023 guidance after Q3 prelim: rev $610-620M, adj EBITDA $150-155M","bullets":["Net revenue prelim Q3 2023 $610-620M, up ~13% YoY.","Adjusted EBITDA $150-155M, up ~21% YoY; income before taxes $18-28M, substantially higher YoY.","Net leverage declined to ~4.6x from 5.3x at Dec 2022 due to higher profitability and debt reduction.","Full-year 2023 guidance raised; Co-CEOs cite momentum from generics, biosimilars, and AvKARE.","IPX203 for Parkinson's on track for potential 2024 launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-23-000035","json":"https://secwatch.observer/filing/0001723128-23-000035.json","markdown":"https://secwatch.observer/filing/0001723128-23-000035.md","text":"https://secwatch.observer/filing/0001723128-23-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000035/0001723128-23-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000035/amrx-20231023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T16:55:51.727164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d8cf80954172b24ec944af17e6fb034fdcdfba7","claim":"Amneal Pharmaceuticals, Inc. reported the third quarter ended September 30, 2023 results: revenue $610 million to $620 million. Guidance raised.","evidence_excerpt":"report actual third quarter 2023 financial results on November 7, 2023. Unaudited Preliminary Financial Results for the Third Quarter Ended September 30, 2023 • Net revenue of $610 million to $620 million, an increase of approximately 13% compared to the third quarter of 2022 • Income before income taxes of $18 million to $28 million, which is substantially higher","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000035/0001723128-23-000035-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$610 million to $620 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}